Abstract Triple negative (TN, tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2)) and HER2-overexpressing (H2E, ER-/HER2?) tumors are two particularly aggressive subtypes of breast cancer. There is a lack of knowledge regarding the etiologies of these cancers and in particular how anthropometric factors are related to risk. We conducted a population-based casecase study consisting of 2659 women aged 20-69 years diagnosed with invasive breast cancer from 2004 to 2012. Four case groups defined based on joint ER/PR/HER2 status were included: TN, H2E, luminal A (ER?/HER2-), and luminal B (ER?/HER2?). Polytomous logistic regression was used to estimate odds ratios (ORs) and associated 95 % confidence intervals (CIs) where luminal A patients served as the reference group. Obese premenopausal women [body mass index (BMI) C30 kg/m 2 ] had an 82 % (95 % CI 1.32-2.51) increased risk of TN breast cancer compared to women whose BMI \25 kg/m 2 , and those in the highest weight quartile (quartiles were categorized based on the distribution among luminal A patients) had a 79 % (95 % CI 1.23-2.64) increased risk of TN disease compared to those in the lowest quartile.
Introduction
Using gene expression profiling, five distinct molecular subtypes of breast cancer have been identified: luminal A, luminal B, HER2-overexpressing, basal-like, and unclassified [1, 2] . Immunohistochemistry (IHC)-based surrogate definitions of these subtypes using protein expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) are routinely used to classify tumors as luminal (ER?), HER2-overexpressing (H2E) (ER-/HER2?), and triple negative (TN) (ER-, PR-, and HER2-which serves as a surrogate for basal-like cancers). TN and H2E are two aggressive subtypes associated with poorer 5-year survival (73-89 % and 52-81 %, respectively) compared to luminal tumors (87-96 %) [3] [4] [5] .
While clinical differences across the molecular subtypes have been well described [3, 6] , etiologic differences have been less studied. Several prior studies including a large pooled analysis of much of the data available worldwide have established that obesity increases risk of postmenopausal breast cancer [7] [8] [9] , but decreases the risk of premenopausal breast cancer [9, 10] . Comparatively few studies [11] [12] [13] [14] [15] [16] [17] [18] have evaluated the relationships between anthropometric factors and risks of different molecular subtypes of breast cancer. Interpretation of these studies is challenged by their relatively small sample sizes as they have included only 50-375 TN cases and 33-117 H2E cases. Nevertheless, among the larger studies [15] [16] [17] there is an increased risk of TN cancers associated with a higher BMI among premenopausal women but no differences in risk among postmenopausal women. To further our understanding regarding the impact of anthropometric factors on the risks for TN and H2E breast cancer, we conducted a population-based case-case study of breast cancer among women aged 20-69 years in western Washington and Albuquerque, New Mexico.
Materials and methods

Patient identification
The study protocol was independently approved by the . Women aged 70 years or older were not included in the study because the incidence of TN and H2E tumors declines sharply after age 70 [19] . Women with incomplete tumor marker information were not eligible for the study. After ascertainment through the population-based Surveillance, Epidemiology and End Results (SEER) cancer registries serving the Seattle-Puget Sound and the state of New Mexico and review of pathology reports for potentially eligible cases, four case groups defined by joint ER/PR/ HER2 status were enrolled including TN (ER-/PR-/ HER2-), H2E (ER-/HER2?), luminal A (ER?/ HER2-), and luminal B (ER?/HER2?). All incident TN and H2E breast cases were targeted for enrollment, but only a random sample of women with incident ER? breast cancer, 75 % of the size of the TN case group and frequency matched to the distribution of age at diagnosis, year of diagnosis, and study site of the combined TN/ H2E case group were eligible for the study. This strategy was used to gain statistical efficiency while containing the cost of the study given that ER? breast cancer is much more common than other subtypes. Subjects were included regardless of vital status and medical records were reviewed for those who were deceased at the time of enrollment through a waiver of consent.
Different approaches were used to recruit participants in New Mexico and Seattle-Puget Sound (Fig. 1) . In New Mexico, medical records of all 681 eligible cases were reviewed under an IRB-approved waiver of consent (participation rate: 100 %) and no individual contact was made with participants. At the Seattle site, two sources were used to recruit cases: (1) 461 eligible cases identified from prior studies with overlapping eligibility criteria (the design and methods have been described previously [20, 21] ); and (2) de novo enrolled cases. Self-reported data obtained through structured interviewer-administered questionnaires were available from all 461 previously enrolled women and medical records were reviewed for 450 of them. In addition, 2363 new cases meeting our eligibility criteria were identified. They were first sent a letter describing the study's purpose and procedure, followed several days later by a telephone call from one of our trained interviewers to answer questions and obtain consent for interview and/or medical records review. A total of 1568 of these 2363 women (65.4 %) were enrolled including 1050 for whom both interview and medical records data were available, 355 for whom medical record data only were available, and 163 for whom only interview data were available. Among the total of 2710 breast cases enrolled at both sites, 51 cases missing height and/or weight data from both sources were excluded from this analysis. Thus, our final analytic sample size consisted of 2659 cases including 1275 TN, 772 luminal A, 129 luminal B, and 483 H2E breast cancer cases.
Data collection
Data on demographic, epidemiologic, and clinical factors were ascertained from a detailed medical records review (both sites) and/or a structured telephone interview (Seattle only). Using the same protocol and instrument across study sites, data on medical records were abstracted from multiple sources including hospitals, oncology practices, and primary care practices to obtain complete data on patient's height and weight at the time of breast cancer diagnosis. In addition, information on a variety of breast cancer risk factors was obtained, including reproductive history, use of oral contraceptives (OCs), and menopausal hormone therapy (HT) over the five years prior to breast cancer diagnosis, family history of breast cancer, and menopausal status. Information on stage, grade, and ER/PR/HER2 status were collected from pathology, surgery, and laboratory reports. A random 10 % of completed abstracts were exchanged and reviewed between study sites to insure consistency in abstracting approach, methodology, and coding. The primary source of data was medical records and interview data were used to supplement missing medical record data.
Statistical analysis
Body mass index (BMI, kg/m 2 ) at diagnosis was categorized based on WHO criteria (normal: \25 kg/m 2 ; overweight: 25.0-29.9 kg/m 2 ; obese: C30 kg/m 2 ). BMI data abstracted from medical records were available for 2451 (92.2 %) women and interview only data were available for the remaining 208 women. Among 1452 participants whose BMI data were available from both sources, there was 79.4 % agreement (kappa = 0.69) within BMI categories. The level of agreement of BMI data from the two sources was similar across breast cancer subtypes (77.6, 77.1, 81.9, and 76.8 % for luminal A, luminal B, TN, and H2E cases, respectively). In general, self-reported BMI [mean: 27.2 kg/m 2 , standard deviation (SD): 6.5] was lower than BMI abstracted from medical records (mean: 28.3 kg/m 2 , SD: 6.9) among those with data from both sources. Height and weight at diagnosis were analyzed separately, categorized into quartiles based on the distribution of these variables among luminal A patients. The agreement between height and weight was 78.6 % (kappa = 0.71) and 75.9 % (kappa = 0.68) within these quartiles, respectively, with women on average self-reporting a slightly greater height We used polytomous logistic regression to calculate ORs and their associated 95 % confidence intervals (CIs) to estimate the risks for luminal B, TN, and H2E breast cancer relative to luminal A cancer. Luminal A patients served as the reference category for all analyses since this is the most commonly diagnosed breast cancer subtype. All analyses were performed using Stata/SE (Stata Corp, College Station, TX). All models were adjusted for age at diagnosis (5-year categories), year of diagnosis (continuous), and study site. Other variables evaluated as potential confounders (as categorized in Table 1 ) included race/ethnicity, first-degree family history of breast cancer, parity, health insurance, smoking status, recent HT use, and recent OC use, but they did not change the risk estimates by more than 10 % when individually assessed and hence were not added to our final model. Adjustment for height when evaluating weight (and vice versa) did not change ORs by more than 10 %, and therefore, it was not included as a covariate in the final model. Analyses were further stratified by menopausal status and 50 subjects who had unknown menopausal status were excluded in this stratified analysis. Menopausal status was primarily determined based on information from medical records. Perimenopausal cases (n = 223) were included in the premenopausal group. Postmenopausal women included those who had natural menopause or induced menopause by bilateral oophorectomy, and those who were using HT with unknown menstrual status 
Results
Luminal B cases were somewhat younger, more frequently Hispanic, premenopausal, nulliparous, never users of HT, and less likely to be never smokers and to have private health insurance compared to women with other breast cancer subtypes (Table 1) . Women with TN cancers were somewhat more likely to be younger, African American, and to be current users of estrogen only HT. H2E cases were somewhat more likely to be postmenopausal, to have three or more full-term pregnancies and to have used OCs. Luminal A cases were somewhat more likely to be nonHispanic white, to have private insurance, and to be current estrogen ? progestin HT users and OC users compared to women with the other breast cancer subtypes. Compared to luminal A cases, no differences in risk were observed with respect to increasing quartiles of BMI, weight, or height across the breast cancer subtypes based on p values for trend (Table 2) . However, when stratified by menopausal status (Table 2) , both weight and BMI were positively associated with risk for TN breast cancer among premenopausal women (p trend: 0.012 and 0.004, respectively) with a 5 % increase in risk observed per 5 kg increase in weight and a 16 % increase in risk per 5 kg/m 2 increase in BMI. In contrast, we found a 9 % and a 16 % decrease in risk per 5 kg/m 2 increase in BMI for TN and H2E cancers, respectively, among postmenopausal women. A 6 % decrease in risk per 5 kg increase in weight was also observed for H2E disease. Height was not associated with differential risk of breast cancer subtypes among either premenopausal or postmenopausal women.
Discussion
In this population-based case-case study with an appreciably larger sample size than any of the prior published studies, our data suggest that there is heterogeneity in the relationship between BMI and breast cancer molecular subtype risk by menopausal status. While it is well established that obesity is a risk factor for postmenopausal breast cancer with a large pooled analysis of prospective studies suggesting 7 % increased risk per 4 kg/m 2 increase in BMI and 6 % increase per 10 kg increase in weight [9] , our study suggests that obesity may primarily contribute to an increased risk of postmenopausal luminal disease, but not to risk of either TN or H2E breast cancer. This is consistent with earlier cohort [11] and case-control [12] [13] [14] studies, and a meta-analysis [22] that have generally observed no association between BMI and risk of ERbreast cancer among postmenopausal women. The few studies that have employed specific case-case comparisons [12, [15] [16] [17] reported no differential risk of postmenopausal TN or H2E cancers relative to luminal A subtype in relation to BMI. However, these studies had quite limited sample sizes with number of cases ranging from 143 to 375 and 61 to 117 for TN and H2E cancers, respectively. The relationship between obesity and postmenopausal breast cancer is thought to primarily be hormonally driven [23] . The peripheral conversion of androgens to estrogen in adipose tissue is the primary source of estrogen in postmenopausal women, and obesity has been shown to directly translate to higher blood levels of circulating estrogen in older women. [23, 24] Thus, the observation that obesity may primarily impact ER? breast cancer risk is consistent with this mechanism. The correlation between BMI and physical activity levels, a factor we did not have data to control for in this study, may also partly explain the observed associations as some prior studies [25, 26] but not all [27] [28] [29] [30] have reported that the inverse association between physical activity and risk of postmenopausal cancers was limited to or stronger for ER? cancers than ER-cancers. Although some earlier studies have found that the relationship between BMI and breast cancer risk among postmenopausal women is modified by HT use, with elevations in risk restricted to non-users of HT [8, 31, 32] , we did not observe this in our data. A potential reason is that the numbers of HT users has dropped precipitously in recent years such that current HT users comprised \10 % of our study population and consequently we had limited statistical power to evaluate this interaction.
It is also well established that obesity is associated with a reduced risk of premenopausal breast cancer [9, 10] . However, we find that this reduction in risk may be restricted to ER? disease as we observed that compared to women with luminal A breast cancer, obesity was associated with an increased risk of TN breast cancer. This is consistent with prior studies that reported increased risks of TN cancer with higher BMI compared to either cancer-free women [15] or women with luminal A cancers [16] . Although three other studies assessing this association did not find statistically significant relationships, all of their risk estimates were suggestive of an increased risk of TN breast cancer associated with increased BMI in young women [12, 17, 18] .
In premenopausal women, ovaries are the primary source of circulating estrogen. Obesity can result in irregular and less frequent menstrual cycles among premenopausal women and thus a lower cumulative exposure to estrogen [33, 34] , which may contribute to their reduction in risk of ER? disease. Some non-hormonal pathways may also mediate the association between obesity and TN cancers among premenopausal women. Obesity is associated with inflammation, elevated levels of insulin and insulin-like growth factors, and other carcinogens [35, 36] that have been linked to a higher premenopausal breast cancer risk [37] [38] [39] . However, it remains uncertain which specific factors may drive risk of particular breast cancer subtype. The potentially detrimental impact of obesity on risk of premenopausal TN cancers may partly explain the repeatedly observed higher incidence of TN cancers among young African American and Hispanic women compared to non-Hispanic whites [40, 41] . According to data from the 2009 to 2010 National Health and Nutrition Examination Survey, the prevalence of overweight or obesity (BMI C 25 kg/m 2 ) for women between 20 and 39 years of age was 74.2 % for African Americans, 65.4 % for Hispanics, and 50.7 % for non-Hispanic whites [42] .
It is important to acknowledge the limitations of our study. This study compared luminal B, TN, and H2E cases to luminal A breast cancer cases in relation to height, weight, and BMI and thus the associations obtained here should not be interpreted as risks compared to a cancer-free control population. Given the wealth of data and evidence establishing anthropometric factors as risk factors for breast cancer, the approach used here enables efficient evaluation of etiologic heterogeneity across subtypes where the case-case odds ratio is equal to the ratio of the relative risk of developing one subtype of the disease to relative risk of developing the reference subtype [43] . Recall bias is a potential concern for most case-control studies, but in this study anthropometric data for 92.2 % of our sample was obtained from medical records. Further, results were unchanged when analyses were restricted to data ascertained only from medical records. Women with unknown tumor markers were excluded and misclassification of case subtypes is also possible as we abstracted ER, PR, and HER2 information from cancer registries which gather data from various clinics and laboratories with potential variability in practices regarding reading and interpreting these biomarkers; however, any misclassification present is likely non-differential and is unlikely to be related to anthropometric characteristics. We did not have data on some important lifestyle factors such as diet and physical activity which may be correlated with both BMI and risk of certain subtypes of breast cancer. With respect to generalizability, our study included few African American but did recruit a substantially larger number of Hispanic women than have been included in prior etiologic studies of breast cancer subtypes. Also, we reviewed pathology reports and addendums and retrieved tumor marker information for at least 94 % of potentially eligible participants to minimize bias due to exclusion of cases missing tumor marker status. Since active consent was obtained from Seattle but not New Mexico participants, we compared the demographic characteristics of Seattle participants versus non-participants. Participants were somewhat more likely to be older (proportion of women diagnosed between ages 60 and 69 years: 27.7, 25.9, 30.5 % vs. 25.6, 21.7, and 21.8 % for ER?, H2E, and TN cases among those who were enrolled and those who refused, respectively) and non-Hispanic white (88.5, 85.4, 82.8 % vs. 74.8, 62.5, 73.4 % for ER?, H2E, and TN cases among those who were enrolled and those who refused, respectively) compared to non-participants.
Our results add to recent evidence that the role of BMI in pre-and postmenopausal breast cancer differs across the major breast cancer subtypes and adds to our understanding of the etiologies of clinically aggressive TN and H2E tumors. Further clarifying the impact of potentially modifiable risk factors such as BMI according to breast cancer subtype can help inform both the origins of known breast cancer disparities and the development of novel prevention strategies.
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